1. Home
  2. APOG vs RGNX Comparison

APOG vs RGNX Comparison

Compare APOG & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

APOG

Apogee Enterprises Inc.

HOLD

Current Price

$37.21

Market Cap

835.9M

ML Signal

HOLD

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

HOLD

Current Price

$11.39

Market Cap

761.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APOG
RGNX
Founded
1949
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
835.9M
761.9M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
APOG
RGNX
Price
$37.21
$11.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$47.00
$30.38
AVG Volume (30 Days)
339.4K
1.0M
Earning Date
01-07-2026
03-12-2026
Dividend Yield
2.88%
N/A
EPS Growth
N/A
N/A
EPS
1.86
N/A
Revenue
$1,399,073,000.00
$161,318,000.00
Revenue This Year
$4.12
$133.58
Revenue Next Year
N/A
$45.08
P/E Ratio
$20.15
N/A
Revenue Growth
1.59
91.30
52 Week Low
$30.75
$5.04
52 Week High
$53.70
$16.19

Technical Indicators

Market Signals
Indicator
APOG
RGNX
Relative Strength Index (RSI) 47.09 37.29
Support Level $38.06 $9.51
Resistance Level $39.59 $11.78
Average True Range (ATR) 1.25 1.08
MACD 0.08 -0.44
Stochastic Oscillator 38.63 28.59

Price Performance

Historical Comparison
APOG
RGNX

About APOG Apogee Enterprises Inc.

Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: